Sino Biopharmaceutical Ltd. | Mutual Funds
Mutual Funds that own Sino Biopharmaceutical Ltd.
John Hancock III - International Growth Fund
110,419,190
0.87%
29,128,190
1.41%
04/30/2018
Vanguard Emerging Markets Stock Index Fund
99,507,574
0.79%
-770,000
0.15%
07/31/2018
Vanguard Total International Stock Index Fund
90,864,813
0.72%
1,095,000
0.03%
07/31/2018
First State Global Umbrella Fd. Plc - China Growth Fund
81,150,000
0.64%
-27,330,000
2.37%
09/30/2017
Government Pension Fund - Global (The)
70,797,890
0.56%
-24,915,597
0.01%
12/31/2017
iShares Core MSCI Emerging Markets ETF
58,007,000
0.46%
0
0.15%
09/05/2018
Baron Emerging Markets Fund
56,390,961
0.45%
-12,470,169
1.37%
06/30/2018
Harding Loevner Institutional Emerging Markets Portfolio
54,978,757
0.44%
1,784,999
1.48%
06/30/2018
Stichting Pensioenfonds ABP (Global Equity Portfolio)
48,887,886
0.39%
-16,509,174
0.01%
03/31/2018
UBS (Lux) Equity Fund - China Opportunity
46,317,000
0.37%
0
1.56%
01/31/2018
| Address |
Unit 09, 41st Floor, Office Tower
Hong Kong
Hong Kong
|
|
Employees
|
- |
| Website |
http://www.sinobiopharm.com |
| Updated |
07/08/2019 |
| Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. |
